Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aurobindo Pharma Gains 4%; BSE HEALTHCARE Index Up 0.3%
Tue, 13 Aug 13:1

Aurobindo Pharma Gains 4%; BSE HEALTHCARE Index Up 0.3%Image source: Sakorn BernardaSv/www.istockphoto.com

Aurobindo Pharma share price has zoomed 4% and is presently trading at Rs 1,522.4.

Meanwhile, the BSE HEALTHCARE index is at 41,176.7 (up 0.3%).

Among the top gainers in the BSE HEALTHCARE index today are FORTIS HEALTHCARE (up 4.7%) and AJANTA PHARMA (up 3.9%).

Cadila Healthcare (down 5.1%) and ALEMBIC PHARMA (down 2.6%) are among the top losers today.

Over the last one year, Aurobindo Pharma has moved up from Rs 879.1 to Rs 1,522.4, registering a gain of Rs 643.3 (up 73.2%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,485.8 to 41,176.7, registering a gain of 44.6% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 110.7%), GRANULES INDIA (up 110.2%) and SUVEN PHARMACEUTICALS (up 105.2%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 79,314.2 (down 0.4%).

The top losers among the BSE Sensex today are HDFC Bank (down 2.7%) and Tata Motors (down 1.7%). The most traded stocks in the BSE Sensex are Tata Steel and HDFC Bank.

In the meantime, NSE Nifty is at 24,234.3 (down 0.5%). HDFC Bank and HDFC LIFE INSURANCE are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,995.8 to 79,314.2, registering a gain of 13,318.4 points (up 20.2%).

Aurobindo Pharma Financial Update...

Aurobindo Pharma net profit grew 60.6% YoY to Rs 9,196 million for the quarter ended June 2024, compared to a profit of Rs 5,725 million a year ago. Net sales rose 10.5% to Rs 75,670 million during the period as against Rs 68,505 million in April-June 2023.

For the year ended March 2024, Aurobindo Pharma reported 64.4% increase in net profit to Rs 31,690 million compared to net profit of Rs 19,277 million during FY23. Revenue of the company grew 16.7% to Rs 290,019 million during FY24.

The current Price to earnings ratio of Aurobindo Pharma, based on rolling 12 month earnings, stands at 25.2.


Equitymaster requests your view! Post a comment on "Aurobindo Pharma Gains 4%; BSE HEALTHCARE Index Up 0.3%". Click here!